BIO-RAD LABORATORIES, INC. acquires Curiosity Diagnostics sp. z o.o.

BIO-RAD LABORATORIES, INC. acquired Curiosity Diagnostics sp. z o.o. for $137.1 million total consideration, including fair value of contingent consideration of up to $70.0 million payable on technological development and sales milestones, a transaction completed in August 2022, structured as all cash plus contingent consideration.

Curiosity Diagnostics sp. z o.o. operates in Clinical Diagnostics, is based in Poland. Curiosity Diagnostics is a late-stage, pre-commercial platform company developing a sample-to-answer, rapid diagnostics PCR system for the molecular diagnostics market.

The strategic rationale for the transaction was to facilitate our entry into the molecular disease testing market with a differentiated platform.

Differentiated late-stage molecular diagnostics platform complementing Bio-Rad's Clinical Diagnostics offerings. Facilitates entry into the molecular disease testing market and complements Clinical Diagnostics product offerings. Clinical Diagnostics segment Per FY2025 10-K: in December 2025 Bio-Rad discontinued development of the IPR&D asset associated with the Curiosity acquisition and recorded an impairment charge of $127.7 million.

Curiosity Diagnostics, a late-stage, pre-commercial platform company, is in the process of developing a sample-to-answer, rapid diagnostics PCR system for the molecular diagnostics market.Bio-Rad Laboratories FY2022 10-K, Acquisition note

Advisory firms were not disclosed for this transaction.

You're subscribed.

Thanks for signing up.